Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women

TABLE 4

Changes between baseline and 3 months in the troglitazone nonresponders and responders

Non-responders* Responders P
n 35 73
Fasting glucose (mg/dl) −1.0 (−26.0, 50.0) −4.0 (−26.0, 10.0) 0.008
Kg (min−1/100) −0.01 (−0.53, 0.75) 0.06 (−1.69, 1.75) 0.12
SI (min−1 per μU/ml × 10−4) −0.09 (−2.13, 0.44) 1.41 (0.54, 7.67) <0.000
Total insulin area (μU/ml × min) −287 (−7,517, 4,487) −2,717 (−19,364, 985) <0.000
AIRg (μU/ml × min) 18 (−769, 341) −15 (−926, 364) 0.04
DI −6 (−1,010, 625) 477 (−1,822, 2,732) <0.000
Pill compliance (% of prescribed)§ 87 (20, 100) 90 (46, 99) 0.78
  • Data are median (minimum, maximum). P values for difference between groups, by Wilcoxon’s rank-sum test.

  • *

    * Tertile 1 for change in SI, Table 3;

  • tertiles 2 and 3 for change in SI, Table 3;

  • P < 0.01 for change from baseline within a group by Wilcoxon’s signed-rank test;

  • §

    § during first 3 months on trial.

This Article

  1. Diabetes vol. 51 no. 9 2796-2803